TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15911548
Drug: Fosfomycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (single dose)
Study: 12644731
Drug: Acamprosate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate therapy
Study: 12644731
Drug: Standard cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cohort (no pharmacotherapy)
Study: 10596714
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin (300 mg b.i.d.)
Study: 10596714
Drug: Intravenous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceftazidime (1 g i.v. t.d.)
Study: 6742528
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with a commercial standardized aluminum hydroxide‐bound dog dander extract (15 subjects)
Study: 6742528
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections containing histamine (12 subjects)
Study: 31831074
Drug: Biopsychosocial multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsychosocial multidisciplinary intervention (physiotherapy, cognitive-behavioral therapy, medication)
Study: 12479191
Drug: Esmolol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1.0 mg x kg(‐1) and Nicardipine 30 microg x kg(‐1)
Study: 8545860
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 1‐2 mg/kg/day
Study: 28561987
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol and Foleys catheter
Study: 25327872
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol alone
Study: 17426465
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg, n=30)
Study: 12108888
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment modifications including extent of staging work-up, radiation field size and dose, optimal chemotherapy regimen, number of cycles of chemotherapy, limited- vs extended-field radiation therapy and dose.
Study: 12108888
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone in early-stage patients.
Study: 9796090
Drug: Low-dose estradiol-releasing
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estradiol-releasing vaginal ring
Study: 2523663
Drug: Isradipine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (various doses)
Study: 2523663
Drug: Isradipine (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (doses above 10 mg per day)
Study: 1071960
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diuretic and propranolol
Study: 19736165
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (aspirin, thienopyridine, cilostazol)
Study: 7584277
Drug: Faces with
Normalized name: Face Up with Sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faces with two names (e.g., actors playing nameable characters)
Study: 29685815
Drug: Eculizumab (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (900 mg)
Study: 25023799
Drug: DRC-based diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRC-based diet with 0% WDGS and 84 mg/steer ZH
Study: 25023799
Drug: DRC-based diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRC-based diet with 30% WDGS and 84 mg/steer of ZH
Study: 18261965
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg (BMI ≤50 kg/m2) or 60 mg (BMI >50 kg/m2) every 12 hours during hospitalization and once daily for 10 days after discharge
Study: 7488301
Drug: Retard capsule
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retard capsule containing 20 mg PE hydrochloride and 4 mg CA maleate
Study: 7488301
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of the same active principles
Study: 7488301
Drug: Retard capsule
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retard capsule under repeated dosing conditions (one capsule b.i.d. during 4 days)
Study: 2298357
Drug: Laxative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative preparation
Study: 2298357
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no laxative preparation)
Study: 6155029
Drug: Zinc sulfate,
Normalized name: Zinc sulfate, anhydrous
DrugBank: Zinc sulfate (DB09322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc sulfate, 440 mg total daily dose
Study: 30931663
Drug: Hi-Fatigue G
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hi-Fatigue G
Study: 22422304
Drug: Cholecalciferol 2,000
Normalized name: CHOLECALCIFEROL 2,000UNIT TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 2,000 IU daily
Study: 22422304
Drug: Cholecalciferol 5,000
Normalized name: CHOLECALCIFEROL 5,000UNIT CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 5,000 IU daily
Study: 21542916
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment as recommended by 4‐T staff
Study: 21542916
Drug: 4‐T automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐T automated insulin dose adjustment algorithm
Study: 17151589
Drug: Spread 1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spread 1 (200 microg folic acid, 2 microg vitamin B(12), 1 mg vitamin B(6))
Study: 17151589
Drug: Spread 2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spread 2 (400 microg folic acid, 2 microg vitamin B(12), 1 mg vitamin B(6))
Study: 9692698
Drug: Mosapride 40
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 40 mg q.d.s. for 2 days
Study: 7919152
Drug: Caffeine (adenosine-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (adenosine-receptor antagonist)
Study: 3079536
Drug: Oral glucose/electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose/electrolyte solution designed for maintenance of hydration (Na+ concentration 45 mmol/l)
Study: 3079536
Drug: Oral glucose/electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose/electrolyte solution designed for fluid replacement (Na+ concentration 75 mmol/l)
Study: 11557312
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (12.5 mg/kg body weight) and N-acetyl-cysteine (10 mg/kg body weight) for 7 days
Study: 9663892
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 5 mg folic acid daily for 40 weeks
Study: 9663892
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 5 mg folic acid daily for 52 weeks
Study: 7852661
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg cyanocobalamin (3 x/day)
Study: 23090813
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Methylphenidate (MPH)
Study: 23300127
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy for Antidepressants (META)
Study: 21361737
Drug: Ingesting 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingesting 10 tablets (four acetaminophen, four ibuprofen, and two multivitamin tablets) with 500 ml of water
Study: 21361737
Drug: Drinking 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking 500 ml of water alone (control group)
Study: 12538743
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg orally for 6 weeks)
Study: 12538743
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg orally for 6 weeks)
Study: 12538743
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antihypertensive drugs except diuretics)
Study: 11195946
Drug: Concurrent knowledge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent knowledge of clinical ear status
Study: 3812946
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml 0.5% prilocaine
Study: 3812946
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 1% prilocaine
Study: 3812946
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml 1% prilocaine
Study: 3812946
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg prilocaine
Study: 29575488
Drug: Internal connection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal connection and microthreads on the implant neck (I MT)
Study: 26345106
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing plus 375 mg amoxicillin and 250 mg metronidazole for 7 days
Study: 23905537
Drug: Therapist responsiveness
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist responsiveness in the first two sessions of therapy (Cognitive Behavior Therapy and Interpersonal Psychotherapy)
Study: 20124051
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate therapy for 28 days
Study: 20124051
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate therapy
Study: 19103540
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) added to induction cardioplegia solution at a dose of 4 mmol/l and to maintenance cardioplegia solution at a dose of 2 mmol/l
Study: 11127492
Drug: Educational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational group sessions and individual sessions administered by a trained nurse and physiotherapist for COPD patients.
Study: 3101243
Drug: Intramuscular iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iron dextran prophylaxis
Study: 29089053
Drug: Fluralaner (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluralaner (1.5 mg/kg body weight, 4 administrations, 7 days apart)
Study: 24019110
Drug: Colesevelam (3,750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (3,750 mg once daily) administered simultaneously with glimepiride
Study: 24019110
Drug: Colesevelam (3,750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (3,750 mg once daily) administered simultaneously with glipizide ER
Study: 24019110
Drug: Colesevelam (3,750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (3,750 mg once daily) administered simultaneously with olmesartan medoxomil
Study: 24019110
Drug: Colesevelam (3,750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (3,750 mg once daily) administered 4 hours before glimepiride
Study: 24019110
Drug: Colesevelam (3,750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (3,750 mg once daily) administered 4 hours before glipizide ER
Study: 24019110
Drug: Colesevelam (3,750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (3,750 mg once daily) administered 4 hours before olmesartan medoxomil
Study: 21781231
Drug: Zinc-aluminium ointment
Normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc-aluminium ointment
Study: 20087302
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (0.8% BCAA in a 3.5% carbohydrate solution; 2,500 mL/day)
Study: 17535868
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated TS)
Study: 9168213
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg administered directly in the surgical site (mixed with local anesthetic)
Study: 9168213
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg administered via the parenteral route
Study: 1438525
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg b.d.) with MMSC (500 mg four times daily)
Study: 1438525
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg b.d.) with cysteine (200 mg four times daily)
Study: 1438525
Drug: Cimetidine alone
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine alone (previous treatment)
Study: 2410683
Drug: Prazosin (5.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (5.7 mg/day)
Study: 25515163
Drug: Classical method
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical method of esophageal speech therapy
Study: 23808506
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (bolus of 8 to 15 ml of ropivacaine 0.2% and infusion of 5 to 15 ml/hour for three days)
Study: 23808506
Drug: Transversus abdominis
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus abdominis plane block (bolus dose of 20 ml of ropivacaine 0.375% bilaterally and infusion of 0.2% ropivacaine 8 ml/hour bilaterally for three days)
Study: 20623443
Drug: Fiber-free diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-free diet (FFD) with polyethylene glycol electrolyte solution (PEG-ES)
Study: 20623443
Drug: Clear-liquid diet
Normalized name: Metamucil Clear & Natural Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear-liquid diet (CLD) with polyethylene glycol electrolyte solution (PEG-ES)
Study: 18972726
Drug: Chinese drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drug Yueyue-shu (Control)
Study: 16377669
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg) alone
Study: 16377669
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg) with antacid (Maalox containing 600 mg magnesium hydroxide and 900 mg aluminum hydroxide)
Study: 12754130
Drug: Methotrexate 12.3±3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 12.3±3.6 mg once a week + Meloxicam 7.5 mg for 3 months
Study: 12754130
Drug: Methotrexate 21.3±3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 21.3±3.2 mg once a week + Meloxicam 7.5 mg for 3 months
Study: 1330676
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (0.5 mg/ml)
Study: 1330676
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (2.5 mg/ml)
Study: 1330676
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (10 mg/ml)
Study: 31095117
Drug: 20 mL 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.5% ropivacaine and 1 ug/kg of dexmedetomidine (group RD)
Study: 31095117
Drug: 20 mL 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.5% ropivacaine (group R)
Study: 28339165
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate nasal spray
Study: 16216821
Drug: Self management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self management using a point of care device to measure INR twice a week and a dosing chart
Study: 14589256
Drug: Medical care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical care plus physical therapy
Study: 10541320
Drug: Maternal receipt
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal receipt of antibiotic in the 24 hours before delivery
Study: 2339012
Drug: lidocaine 5
Normalized name: lidocaine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 5 mg/kg
Study: 24197584
Drug: Levosimendan therapy
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan therapy
Study: 19187340
Drug: PGE(2) infusion
Normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE(2) infusion (0.40 microg kg(‐1) min(‐1))
Study: 11536222
Drug: Modified-release (MR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release (MR) dosage forms of metformin
Study: 11536222
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) dosage forms of metformin
Study: 11536222
Drug: Modified-release (MR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release (MR) formulations of metformin
Study: 11536222
Drug: Extended convolution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended convolution approach modeling absorption using a Hill function
Study: 9340970
Drug: Platinum containing
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum containing re‐induction chemotherapy
Study: 9340970
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment (tamoxifen or GnRH analogues)
Study: 9340970
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with topoisomerase blocking agents, taxanes, or alkylating agents
Study: 8485203
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for AML M4Eo
Study: 23528580
Drug: Mexidol (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (375 mg daily)
Study: 23528580
Drug: Antidepressants (fevarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (fevarin 150 mg daily)
Study: 18950383
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dose of amitriptyline
Study: 16192503
Drug: Clamp‐crushing method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clamp‐crushing method (CC group)
Study: 12452403
Drug: Hypnosis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis treatment (seven biweekly sessions and home audiotapes)
Study: 2755712
Drug: Hypnosis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis treatment
Study: 10599010
Drug: Intensive counselling
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive counselling at the start of treatment and at each subsequent visit for ambulatory patients, or weekly for hospitalised patients.
Study: 7075566
Drug: New simpler
Approvals — FDA: no, EMA: no, PMDA: no
Description: New simpler oral cleansing preparation
Study: 31962346
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment for primary headache (8-11 sessions, including vasoconstriction/vasodilation training for migraine and electromyography training for tension-type headache)
Study: 31962346
Drug: Waiting control
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting control group (no treatment)
Study: 29985874
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (EES) at a dose of 50 mg . kg . day
Study: 27684813
Drug: Tablet-based box
Normalized name: ALLERGENIC EXTRACT, BOX ELDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based box trainer (TBT)
Study: 24909799
Drug: β-cryptoxanthin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-cryptoxanthin (0.75 mg/day) plus phytosterols (1.5 g/day)
Study: 24909799
Drug: β-cryptoxanthin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-cryptoxanthin (0.75 mg/day)
Study: 24909799
Drug: phytosterols (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: phytosterols (1.5 g/day)
Study: 23043951
Drug: Prostaglandin F
Normalized name: Prostaglandin F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F (PGF) 2 mL per fish in 2009/2010 season and 5 mL per fish in 2010/2011 season, in addition to carp pituitary extract (6 mg/kg)
Study: 23043951
Drug: Carp pituitary
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carp pituitary extract (6 mg/kg)
Study: 12431041
Drug: Ketotifen fumarate
Normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen fumarate .025% ophthalmic solution
Study: 1299590
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment only (Group A)
Study: 1299590
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g GL intravenously 15 min before thrombolysis (Group B)
Study: 1299590
Drug: 6.25 mg
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.25 mg CA orally 15 min before thrombolytic treatment (Group C)
Study: 1299590
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g GL intravenously before thrombolysis and 6.25 mg CA orally (Group D)
Study: 6380554
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bd tamoxifen
Study: 6380554
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg bd tamoxifen
Study: 27156934
Drug: Tocilizumab 162
Normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 162 mg subcutaneously weekly
Study: 22800352
Drug: Anti-acid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-acid therapy and conventional pharyngo-laryngitis therapy in LPR group